Neurocrine Biosciences Yönetim

Yönetim kriter kontrolleri 4/4

Neurocrine Biosciences CEO'su Kyle Gano, Jan2011 tarihinde atandı, in görev süresi 13.92 yıldır. in toplam yıllık tazminatı $ 5.99M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.1% maaş ve 89.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.13% ine doğrudan sahiptir ve bu hisseler $ 18.33M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7 yıl ve 9.2 yıldır.

Anahtar bilgiler

Kyle Gano

İcra Kurulu Başkanı

US$6.0m

Toplam tazminat

CEO maaş yüzdesi	10.1%
CEO görev süresi	13.9yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	7yrs
Yönetim Kurulu ortalama görev süresi	9.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Kyle Gano'un ücretlendirmesi Neurocrine Biosciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$386m
Jun 30 2024	n/a	n/a	US$339m
Mar 31 2024	n/a	n/a	US$370m
Dec 31 2023	US$6m	US$603k	US$250m
Sep 30 2023	n/a	n/a	US$191m
Jun 30 2023	n/a	n/a	US$176m
Mar 31 2023	n/a	n/a	US$64m
Dec 31 2022	US$5m	US$551k	US$155m
Sep 30 2022	n/a	n/a	US$58m
Jun 30 2022	n/a	n/a	US$12m
Mar 31 2022	n/a	n/a	US$71m
Dec 31 2021	US$6m	US$517k	US$90m
Sep 30 2021	n/a	n/a	US$445m
Jun 30 2021	n/a	n/a	US$365m
Mar 31 2021	n/a	n/a	US$402m
Dec 31 2020	US$7m	US$488k	US$407m
Sep 30 2020	n/a	n/a	US$93m
Jun 30 2020	n/a	n/a	US$205m
Mar 31 2020	n/a	n/a	US$177m
Dec 31 2019	US$5m	US$443k	US$37m
Sep 30 2019	n/a	n/a	US$21m
Jun 30 2019	n/a	n/a	US$18m
Mar 31 2019	n/a	n/a	-US$39m
Dec 31 2018	US$5m	US$403k	US$21m
Sep 30 2018	n/a	n/a	US$10m
Jun 30 2018	n/a	n/a	-US$52m
Mar 31 2018	n/a	n/a	-US$106m
Dec 31 2017	US$2m	US$375k	-US$143m

Tazminat ve Piyasa: Kyle 'ın toplam tazminatı ($USD 5.99M ) UK pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.77M ).

Tazminat ve Kazançlar: Kyle 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Kyle Gano (51 yo)

13.9yrs

Görev süresi

US$5,990,215

Tazminat

Mr. Kyle W. Gano, Ph D., is CEO and Director at Neurocrine Biosciences, Inc since October 11, 2024. He was Chief Business Development and Strategy Officer at Neurocrine Biosciences, Inc. since 2020 until O...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kyle Gano	CEO & Director	13.9yrs	US$5.99m	0.13% $ 18.3m
Matthew Abernethy	Chief Financial Officer	7.1yrs	US$6.06m	0.031% $ 4.3m
Jude Onyia	Chief Scientific Officer	3.1yrs	US$7.22m	0.015% $ 2.1m
Eiry Roberts	Chief Medical Officer	6.9yrs	US$5.87m	0.031% $ 4.2m
Lawrence Steinman	Co-Founder of Neurocrine	no data	Veri yok	Veri yok
Jane Sorensen	Head of Investor Relations	no data	Veri yok	Veri yok
Darin Lippoldt	Chief Legal Officer & Corporate Secretary	10.2yrs	US$4.72m	0.039% $ 5.4m
Julie Cooke	Chief Human Resources Officer	7.3yrs	Veri yok	0.018% $ 2.5m
Eric Benevich	Chief Commercial Officer	9.6yrs	US$5.81m	0.040% $ 5.5m
David Boyer	Chief Corporate Affairs Officer	5.3yrs	Veri yok	0.00037% $ 50.7k
Ingrid Delaet	Chief Regulatory Officer	2.2yrs	Veri yok	0.0025% $ 340.0k
Christopher O'Brien	Exclusive Consultant	6.9yrs	US$3.10m	Veri yok

7.0yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: 0K6R 'un yönetim ekibi deneyimli ve deneyimlidir ( 7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kyle Gano	CEO & Director	less than a year	US$5.99m	0.13% $ 18.3m
Christine Poon	Independent Director	1.4yrs	US$813.45k	0% $ 0
Richard Pops	Independent Director	26.7yrs	US$492.04k	0.031% $ 4.3m
Stephen Sherwin	Independent Director	25.7yrs	US$479.54k	0.024% $ 3.3m
William Rastetter	Independent Chairman of the Board	14.8yrs	US$495.04k	0.037% $ 5.1m
Gary Lyons	Independent Director	31.8yrs	US$460.11k	0.12% $ 16.1m
George Morrow	Independent Director	9.2yrs	US$479.54k	0.0042% $ 569.0k
Kevin Gorman	Director	16.9yrs	US$15.75m	0.51% $ 69.7m
Shalini Sharp	Independent Director	4.8yrs	US$497.11k	0.00098% $ 134.4k
Leslie Norwalk	Independent Director	5.3yrs	US$475.11k	0.00098% $ 134.4k
Johanna Mercier	Independent Director	3.7yrs	US$467.61k	0.0021% $ 283.8k

9.2yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0K6R 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.2 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/21 11:25
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Neurocrine Biosciences, Inc. 50 Bu analistlerden 22, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Martha Freitag	Argus Research Company
Brian Skorney	Baird
Ishan Majumdar	Baptista Research

Neurocrine Biosciences Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Independent Chairman of the Board recently sold US$2.1m worth of stock

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences Announces CEO Changes

Insufficient new directors

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Neurocrine Biosciences, Inc. Announces Retirement of Eiry W. Roberts as Chief Medical Officer

Recent updates

Neurocrine Biosciences, Inc. Announces Commercial Availability of CRENESSITY (Crinecerfont) for Children and Adults with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. Announces FDA Approval of Crenessity (Crinecerfont), A First-In-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. Presents New KINECT-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health with INGREZZA (Valbenazine) Capsules

Neurocrine Biosciences, Inc. Presents Breadth of Data Demonstrating Holistic Improvements over Time in Patients with Tardive Dyskinesia Following Treatment with INGREZZA (Valbenazine) Capsules

Third quarter 2024 earnings released: EPS: US$1.28 (vs US$0.85 in 3Q 2023)

Neurocrine Biosciences, Inc. (NasdaqGS:NBIX) announces an Equity Buyback for $300 million worth of its shares.

Neurocrine Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 19%

Independent Chairman of the Board recently sold US$2.1m worth of stock

Second quarter 2024 earnings released: EPS: US$0.65 (vs US$0.98 in 2Q 2023)

Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Launches INGreZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

Neurocrine Biosciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH

Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis

Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules

First quarter 2024 earnings released: EPS: US$0.43 (vs US$0.79 loss in 1Q 2023)

Insufficient new directors

Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

New minor risk - Shareholder dilution

Full year 2023 earnings released: EPS: US$2.56 (vs US$1.61 in FY 2022)

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024

Sosei Heptares’ Partner Neurocrine Biosciences Confirms Its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Reports Update on the Phase 2 Clinical Trial

Neurocrine Biosciences® Presents Ingrezza® (Valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's Disease Through Week 50 At Huntington Study Group 2023

New minor risk - Shareholder dilution

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.85 (vs US$0.71 in 3Q 2022)

Neurocrine Biosciences, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Application for Ingrezza®? (Valbenazine) Oral Granules Sprinkle Formulation

Neurocrine Biosciences, Inc. Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

Neurocrine Biosciences Inc. Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

Neurocrine Biosciences, Inc. Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders Demonstrating Comparable Improvement over Time in Tardive Dyskinesia Severity and Impact Following Treatment with INGREZZA (Valbenazine) Capsules

Neurocrine Biosciences, Inc. Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

Neurocrine Biosciences, Inc. Announces FDA Approval of INGreZZA (valbenazine) Capsules for the Treatment of Chorea Associated with Huntington's Disease

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.98 (vs US$0.18 loss in 2Q 2022)

Neurocrine Biosciences, Inc. Announces Retirement of Eiry W. Roberts as Chief Medical Officer

Neurocrine Biosciences, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Neurocrine Biosciences, Inc. Presents INGreZZA(R) (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate

Neurocrine Biosciences, Inc. Announces Publication of Full KINECT(TM)-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in the Lancet Neurology

Neurocrine Biosciences, Inc. Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

First quarter 2023 earnings released: US$0.79 loss per share (vs US$0.15 profit in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: EPS: US$1.61 (vs US$0.95 in FY 2021)

Neurocrine Biosciences, Inc. to Report Q4, 2022 Results on Feb 06, 2023

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as A Treatment for Chorea Associated with Huntington Disease

Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-And-Wave During Sleep

Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022

Third quarter 2022 earnings released: EPS: US$0.71 (vs US$0.24 in 3Q 2021)

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full-Year 2022